Illumina Inc

• Illumina surged due to significant price target increases from Wall Street firms. • Strong NovaSeq X placement velocity drove durable fundamental momentum and margin improvements. • Technical indicators show a MACD buy signal and an overbought Williams %R.

• Illumina joined the S&P 500, triggering substantial institutional buying pressure. • Strategic restructuring and GRAIL divestiture drove raised full-year earnings guidance. • Technical indicators show strong buy signals alongside overbought conditions.

• Wall Street upgrades and UBS ratings changes drove Illumina stock upward. • Illumina will rejoin the S&P 500 index during rebalancing. • Annual revenue reached $4.34 billion with a net profit of $850 million.

• UBS upgraded Illumina to Buy with a price target of $260. • Illumina will rejoin the S&P 500 index from the S&P MidCap 400. • The company reported strong NovaSeq X demand and consecutive earnings beats.

• Stryker's stock declined following an earnings miss and contraction in operating margins. • Management lowered forward-looking guidance due to inflationary pressures and cooling elective procedure demand. • Analysts reduced price targets as automated selling programs accelerated downward stock momentum.